Rise predicted for graft versus host disease
The rates of both acute and chronic graft versus host disease (GvHD) will continue to increase over the next eight years, according to a new analysis.
In their report ‘Graft Versus Host Disease: Epidemiology Forecast to 2028’, the analytics company GlobalData estimate that the rate will increase by 2.18% per year.
The report, published on 9th January, covers seven major markets – the US, France, Germany, Italy, Spain, the UK, and Japan. There were about 18,000 GvHD cases in 2018, which is expected to reach 22,500 cases in 2028.
Bishal Bhandari, Senior Epidemiologist at GlobalData, explains that the rise is partly due to the rising trend in transplantation in these countries, as well as wider “demographic changes”.
He says: “GlobalData’s research shows that cases of [acute and chronic GvHD] are growing steadily in the seven major markets.
“The incidence of both is directly dependent on the contribution of transplant practice-related factors, including donor-recipient parity, graft source, donor source, age, and GvHD prophylaxis. As the transplant cases will continue to rise, we expect … cases to rise as well in the near future.
“It is a promising development that the majority of [acute GvHD] cases are now diagnosed at an earlier grade which would respond better to therapy to get [acute GvHD] under control.
“The majority of [chronic GvHD] cases were in moderate and severe grades suggesting that the threat of morbidity and mortality is high and targeted therapy is needed to control the more severe form of [chronic GvHD] cases.”
Disclaimer: The news stories shared on this site are used as a way to inform our members and followers of updates and relevant information happening in Haematology. The BSH does not endorse the content of news items from external sources, and is not in a position to verify the findings, accuracy or the source of any studies mentioned. Any medical or drugs information is provided as an information resource only, and is not to be relied on for any diagnostic or treatment purposes.
News service provided by Englemed News http://www.englemed.co.uk/